EndoPredict combines clinicopathological and molecular results to identify the true low-risk patient. EndoPredict offers a clear low-risk or high-risk result presented on a continuous curve.

Low Risk

  • The risk of distant recurrence within 10 years of initial diagnosis when treated with 5 years of endocrine therapy alone is 4% on average. Up to 73% of patients with node negative disease receive a low risk score (ref Filipits, Buus and Sestak).

High Risk

  • The risk of distant recurrence within 10 years of initial diagnosis when treated with 5 years endocrine therapy alone is above 10%.

In addition to a clear low- or high-risk result, a personalized risk of recurrence is provided based on each patient’s individual tumor.